Angiogenesis is vital in the process of primary tumor growth,proliferation and metastasis.In many cancers,including non-small cell lung cancer (NSCLC),inhibition of tumor angiogenesis has been identified as an important therapy.The most common drugs include bevacizumab,ramucirumab,tyrosine kinase inhibitor such as sorafenib tosylate,and nintedanib.We will summarize the research about some inhibition of tumor angiogenesis.